News

PhaseV to Showcase Innovative Clinical Trial Solutions

PhaseV to Showcase Innovative Clinical Trial Solutions

PhaseV to Showcase Innovations at Major Healthcare and Technology Events

Exploring Machine Learning Solutions for Clinical Trial Optimization

PhaseV, recognized for its pioneering contributions to clinical trial optimization through machine learning, has announced its participation in several key industry events in the upcoming months. As clinical trials continue to evolve, machine learning tools are becoming essential for drug developers looking to improve trial efficiency and address new challenges.

Upcoming Presentations by PhaseV Leaders

Executives from the company will tackle important topics at various prestigious conferences, showcasing the effectiveness of their advanced trial optimization platforms.

European Society For Medical Oncology (ESMO) Congress

PhaseV will be presenting at the ESMO Congress taking place from September 13–17 in Barcelona. This event features the latest research in oncology.

  • Presentation: 1342P: Efficacy of Pembrolizumab vs. Nivolumab Plus Ipilimumab in Metastatic NSCLC in Relation to PD-L1 and TMB Status
  • Speakers: Walid Shalata, MD, and Dan Goldstaub, PhD
  • Date/Time: Saturday, September 14

ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop

This important workshop is scheduled for September 25–27 in Rockville, MD, focusing on regulatory challenges in biopharmaceutical statistics.

  • Presentations:
    • 3823: Comparative Analysis of Immunotherapy Alternatives in Non-Small-Cell Lung Cancer - Elad Berkman, CTO of PhaseV
    • 3806: Model Guided Parameter Optimization for Complex Innovative Trial Designs - Tzviel Frostig, PhD
  • Date/Time: Both presentations will take place on September 26 at 5:45pm EDT

Italian Tech Week

Another exciting event is the Italian Tech Week, happening from September 25–27 in Turin, which will highlight innovative technology in pharmaceutical development.

  • Panel Topic: The Pharma of the Future: Robots, AI, and Adaptive Trials
  • Speakers: Raviv Pryluk, Fred Manby, and Fred Parietti
  • Moderator: Ileana Pirozzi
  • Date/Time: September 25, from 3:02–3:27pm CET

Bayesian Biostatistics Conference Bayes 2024

From October 23–25 in Rockville, PhaseV will delve into groundbreaking discussions on Bayesian biostatistics.

  • Presentations:
    • To Bayes or Not to Bayes: Challenges in Designing Bayesian Adaptive Trials - Raviv Pryluk, PhD
    • The Wolf Will Live with the Lamb: Enhancing Detection in Clinical Trials - Oshri Machluf
  • Date/Times: Raviv will present on October 23 from 2:10–2:30pm EDT, and Oshri will present on October 24 from 11:35–11:55am EDT

Innovation in PhaseV's Platforms

Since its founding, PhaseV's unique machine learning platform has revolutionized the clinical trial landscape, enabling researchers to design and adapt trials more effectively. This technology allows users to quickly analyze a wide range of parameters, aiming for optimal outcomes that align with trial goals.

In addition, PhaseV has introduced a new causal-ML pipeline that reveals hidden signals within clinical data, improving the understanding of treatment effects across various patient groups. This advancement provides invaluable insights to help refine future trial designs, ultimately increasing success rates.

About PhaseV

PhaseV utilizes cutting-edge machine learning techniques to enhance the clinical trial process. The company is dedicated to transforming clinical trial methodologies to ensure that new treatments are distributed to patients more quickly and efficiently. To discover more about their pioneering work, visit www.phaseVtrials.com and connect with them on LinkedIn.

Frequently Asked Questions

What is PhaseV?

PhaseV is an innovative company that focuses on leveraging machine learning to optimize clinical trials, assisting drug developers in improving trial outcomes.

What events will PhaseV be presenting at?

PhaseV will participate in the ESMO Congress, ASA Biopharmaceutical Workshop, Italian Tech Week, and the Bayesian Biostatistics Conference.

How does machine learning facilitate clinical trial design?

Machine learning enables researchers to quickly analyze a multitude of parameters, leading to optimal trial designs that fulfill specific objectives.

Who are some key speakers representing PhaseV?

Key speakers include CEO Raviv Pryluk, CTO Elad Berkman, and Data Scientist Oshri Machluf, who will share their insights and findings at these events.

Where can I learn more about PhaseV's technology?

For more information about PhaseV’s innovative technology, visit their official website at www.phaseVtrials.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Quay Sunglasses: Luxury Looks, Affordable Prices

Updated Category News Views 2

Ah, sunglasses—the quintessential accessory that screams both practicality and style. A million-dollar look without the million-dollar expense? That's where Quay comes in. They've been recognized by Expert Consumers, no less, as some of the best-in-class for affordable luxury eye candy out there—aimed at shoppers who want the designer vibe without the hemorrhaging...

Continue Reading
CVS Health Under Fire: Fiduciary Duty Breach?

Updated Category News Views 2

CVS Under Regulatory Spotlight for Fiduciary Breaches You'd think by now companies would have their fiduciary ducks in a row. But here we are, with CVS Health Corporation (NYSE: CVS) catching heat from the legal eagles over at Halper Sadeh LLC. The knife’s out for some of the big wigs – apparently, there's chatter they might’ve slipped on their duty to play nice...

Continue Reading
Krispy Kreme Faces Legal Probe: Fiduciary Breach?

Updated Category News Views 3

Diving Deep into the Krispy Kreme Allegations Look, this isn't your run-of-the-mill donut drama. When you hear rumblings of corporate missteps, especially ones that involve potential breaches of fiduciary duties, it's time to perk up those ears. Over at Krispy Kreme, Inc. (NASDAQ:DNUT), there's some heat in the kitchen, and it's not just from frying those glazed beauties....

Continue Reading
HONA Faces Legal Heat: Investor Lawsuit Over Losses

Updated Category News Views 5

The Investor Storm Brewing Over Honeywell Aerospace There it is again, another industry heavyweight caught in a dizzying whirlwind of litigation. Honeywell Aerospace Inc. (NASDAQ:HONA), a name as established as an old boot in the business, now faces a class action lawsuit that's got investors frantically dusting off phone numbers for their attorneys. The Messy Allegations...

Continue Reading
PACS Group Faces Legal Scrutiny: What to Watch

Updated Category News Views 3

PACS Group: Legal Storm Brewing Welcome to the latest saga in the volatile theater of corporate governance. PACS Group, Inc., ticker symbol NYSE:PACS, is under the microscope, and not for debuting a groundbreaking product or hitting a stock milestone. Nope, instead we've got Halper Sadeh LLC out of New York investigating some possible hanky-panky from PACS directors and...

Continue Reading
Geron Corp Faces Fiduciary Duty Investigation

Updated Category News Views 4

Spotlight on Geron's Corporate Governance: What's Happening? The heat's been turned up on Geron Corporation this week, with Halper Sadeh LLC, an investor rights law outfit, digging into whether some folks at the helm have strayed from their fiduciary duties to the shareholders. Now, if you're holding onto NASDAQ:GERN stock or thinking about diving in, it's high time to...

Continue Reading
Jackson Wang's Fantasy IP Hits Hong Kong Stage

Updated Category News Views 4

A Star-Studded Fantasy Comes Alive Hong Kong isn't just about dim sum and skyline views—it's a magnet for celebrity showcases, and this time, Jackson Wang's pulling the strings. The guy's ventured beyond music and idol fame, diving head-first into creative visuals with his fantasy IP, "Under the Castle" (UTC). Pairing up with Ocean Park's Halloween Fest, he's cooked up...

Continue Reading
AI and Storytelling Make Waves in Science Education

Updated Category News Views 4

University's Innovative Approach to Learning Alright, here's something you don't see every day. The University of Phoenix managed to snag some kudos from an academic journal for using AI and storytelling to teach environmental science. That's like hitting two bulls-eyes with one shot in the world of education. The recognition from Glacies for this Editor's Choice paper...

Continue Reading

Top 5 Most Recently Viewed Articles

FMC Corporation Transitions by Selling Global Specialty Solutions

Updated Category News Views 137

FMC Corporation Transitions by Selling Global Specialty Solutions FMC Corporation (NYSE: FMC), a prominent player in the agricultural sciences sector, has recently completed the sale of its Global Specialty Solutions business. This significant transaction marks a decisive shift in the company's focus to enhance its core operations and streamline its offerings in the...

Continue Reading
CG Oncology's Promising Future: Analysts Highlight Key Developments

Updated Category News Views 88

Analyst Coverage Boosts CG Oncology's Market Prospects Recently, CG Oncology (NASDAQ:CGON) garnered attention when UBS initiated coverage, assigning a Buy rating with an ambitious price target of $60.00. This endorsement underscores the potential of the company’s flagship program, cretostimogene (creto), which targets non-muscle invasive bladder cancer (NMIBC). Positive...

Continue Reading
Current Trends in Cryptocurrency Market: Key Insights

Updated Category News Views 386

Bearish Pressures on Major Cryptocurrencies In recent days, cryptocurrencies have faced significant bearish trends, with only XRP showing some resilience. This decline raises important questions for traders and investors navigating the volatile crypto landscape. Market Overview: Key Cryptocurrency Prices Here are the current prices and performance metrics for the leading...

Continue Reading
Enhanced Cancer Guidelines Include Key Insights on LEMS

Updated Category News Views 146

Updated Guidelines for LEMS and SCLC In a significant advancement, the National Comprehensive Cancer Network (NCCN) has included essential recommendations for Lambert Eaton Myasthenic Syndrome (LEMS) in their Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC). Importance of VGCC Antibody Testing The updated guidelines emphasize the crucial role of VGCC...

Continue Reading
VEON Invests in Ukraine: Commitment to Digital Growth

Updated Category News Views 102

VEON's Commitment to Investing in Ukraine VEON Ltd. (NASDAQ: VEON), a leading global digital operator, has recently made significant news with its promise to enhance Ukraine’s telecommunications infrastructure. In collaboration with its fully-owned subsidiary, Kyivstar, VEON participated in the 2024 Yalta European Strategy (YES) Annual Meeting. At this event, the focus...

Continue Reading